Key Takeaways
- •On July 22, 2026, the Information Technology and Innovation Foundation (ITIF) published a blog post arguing that the U.S.
- •The ITIF blog emphasizes that the FDA's current regulatory framework may be insufficient to address the risks associated with untested peptides.
- •The ITIF blog post highlights several key dangers of adding untested peptides to compounded medications.
ITIF Calls for FDA to Bar Untested Peptides from Compounded Drugs
On July 22, 2026, the Information Technology and Innovation Foundation (ITIF) published a blog post arguing that the U.S. Food and Drug Administration (FDA) should not permit untested peptides to be added into patients' medications. The piece, hosted on ITIF's official blog, raises concerns about the practice of incorporating unapproved peptide compounds into prescription drugs, particularly in the context of pharmacy compounding.
The ITIF blog emphasizes that the FDA's current regulatory framework may be insufficient to address the risks associated with untested peptides. The foundation argues that allowing such substances into medications without rigorous clinical testing could expose patients to unknown side effects, contamination, or ineffective treatments. The post calls for the FDA to take a firm stance against this practice until proper safety and efficacy data are available.
Risks of Untested Peptides in Patient Care
The ITIF blog post highlights several key dangers of adding untested peptides to compounded medications. Peptides are short chains of amino acids that can have potent biological effects, but without FDA approval, their safety profiles remain unverified. The blog warns that patients receiving these substances may face unpredictable reactions, including allergic responses, toxicity, or interference with other medications.
Compounding pharmacies sometimes add peptides to custom medications for individual patients, but the ITIF argues that this practice bypasses the standard drug approval process. The blog notes that the FDA has limited authority to oversee compounded drugs, and that adding unapproved peptides compounds this regulatory gap. The foundation urges the agency to use its existing powers to prevent such practices and to issue clear guidance prohibiting the use of untested peptides in compounded formulations.
Regulatory Gaps and Public Health Concerns
The ITIF blog post points to a broader regulatory gap that allows untested peptides to enter the pharmaceutical supply chain. While the FDA approves peptides as active ingredients in some prescription drugs, many other peptides are marketed as research chemicals or dietary supplements without FDA oversight. The blog argues that compounding pharmacies should not be able to exploit this loophole by incorporating these unapproved substances into patient medications.
The foundation calls for the FDA to take a more proactive role in monitoring and regulating peptide use in compounding. This includes requiring pharmacies to verify the source and purity of any peptides they use, and to demonstrate that the peptide has a legitimate medical purpose supported by evidence. The ITIF blog suggests that without such measures, patients could be exposed to significant harm without any corresponding benefit.
The Need for Stronger FDA Enforcement
The ITIF blog post concludes by urging the FDA to strengthen its enforcement actions against pharmacies that add untested peptides to medications. The foundation argues that the agency should issue warning letters, seize products, and pursue legal action against violators. The blog also recommends that the FDA work with state pharmacy boards to ensure consistent oversight across the country.
The ITIF blog post is part of a broader conversation about the safety of compounded drugs and the role of the FDA in protecting patients. The foundation's position is that the agency should err on the side of caution and not allow untested peptides to be added into patients' medications until their safety and efficacy are proven through rigorous clinical trials. The blog serves as a call to action for regulators, healthcare providers, and patients to be aware of the risks associated with this practice.
Frequently Asked Questions
Q: What are untested peptides, and why are they a concern in medications?
A: Untested peptides are amino acid chains that have not undergone FDA approval for safety and efficacy. Adding them to compounded medications poses risks of unknown side effects, contamination, or ineffective treatment, as their biological effects are not well understood.
Q: What did the ITIF blog post specifically argue about the FDA's role?
A: The ITIF blog post argued that the FDA should not allow untested peptides to be added into patients' medications. It called for stronger regulatory oversight, including prohibiting the use of unapproved peptides in compounded drugs and enforcing existing laws.
Q: How does [compounding pharmacy](/tools/peptide-pharmacy-verification) practice relate to this issue?
A: Compounding pharmacies sometimes add peptides to custom medications for individual patients. The ITIF blog argues that this practice bypasses the standard drug approval process and exploits regulatory gaps, potentially exposing patients to harm.
Q: What actions did the ITIF recommend the FDA take?
A: The ITIF recommended that the FDA issue clear guidance prohibiting untested peptides in compounded drugs, require pharmacies to verify peptide sources and purity, and strengthen enforcement actions such as warning letters, product seizures, and legal action against violators.
Q: When was the ITIF blog post published, and where can it be found?
A: The blog post was published on July 22, 2026, on the Information Technology and Innovation Foundation's official blog. It is part of the foundation's ongoing analysis of technology and regulatory policy issues.